- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03733145
Angiotensin II in General Anesthesia
May 2, 2023 updated by: Wake Forest University Health Sciences
A Dose Finding Trial for Angiotensin II in Hypertensive Adults on Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Anesthesia-Mediated Hypotension
Hypotension in adult patients undergoing general anesthesia is common.
This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress.
This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs).
Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.
Study Overview
Detailed Description
Hypotension in adult patients undergoing general anesthesia is common.
Many of the body's normal mechanisms to maintain adequate blood pressure in the non-anesthetized state are significantly altered by anesthetic agents, which may lead to hypotension.
This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress.
In response to this it has become standard of care to attempt to maintain blood pressure levels within 20% of baseline in most patients under anesthesia.
Maintaining the baseline blood pressure is important as patients may have pathology such as coronary artery disease, carotid stenosis, and renal artery stenosis, and hypotension may compromise the perfusion of these organs.
Vasodilation also plays a key role in hypotension due to general anesthesia.
Therefore, the intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.The objective of this study is to determine the infusion rate of Ang II that is necessary to return systolic blood pressure (SBP) to within 5% of baseline or greater in patients with essential hypertension taking ACE inhibitors, ARBs, or different classes of antihypertensive agents and further to determine the plasma levels of different RAAS components
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rohesh Fernando, MD
- Phone Number: 3367162712
- Email: rfernan@wakehealth.edu
Study Contact Backup
- Name: Thomas Templeton, MD
- Phone Number: 3367164285
- Email: ttemplet@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Medical Center
-
Contact:
- Rohesh Fernando, MD
- Phone Number: 336-716-2712
- Email: rfernan@wakehealth.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of hypertension and treatment with at least one medication including an ACE inhibitor, ARB, and other agents for greater than 2 months
- Patients undergoing general anesthesia
Exclusion Criteria:
- BMI > 40
- History of deep venous thrombosis / thromboembolic disease
- History of stroke,
- Baseline SBP of ≥ 160 mmHg,
- History of myocardial infarction or cardiac stents
- Difficult airway
- Asthma
- Congestive heart failure
- Chronic obstructive pulmonary disease
- Pregnant patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants on ACE inhibitors
Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group.
Intervention: Drug: Angiotensin II.
|
Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV.
The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
Other Names:
|
Experimental: Participants on ARBs
Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group.
Intervention: Drug: Angiotensin II.
|
Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV.
The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
Other Names:
|
Experimental: Other Classes of Antihypertensive Agents
Participants taking any other class of Antihypertensive Agents will be placed into this group.
Intervention: Drug: Angiotensin II.
|
Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV.
The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean dose required to increase the SBP
Time Frame: up to 1 hour
|
The mean dose required to increase the SBP in these 3 cohorts with essential hypertension (ACE inhibitor, ARB, or those on another class of hypertensive agents) to within 5% of baseline or higher will be calculated.
|
up to 1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean value of Bradykinin
Time Frame: up to 1 hour
|
Mean values of Bradykinin 1-8 and Bradykinin 1-7 will be calculated and reported.
|
up to 1 hour
|
Mean value of Angiontensin
Time Frame: up to 1 hour
|
Mean values of Angiotensin I, Angiotensin II, Angiotensin IV, Angiotensin 1-7, Angiotensin 1-5, Angiotensin 1-9, Angiotensin 2-10, Angiotensin 2-7, and Angiotensin 3-7 will be calculated and reported.
|
up to 1 hour
|
Mean value of Aldosterone
Time Frame: up to 1 hour
|
Mean value of Aldosterone will be calculated and reported.
|
up to 1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.
- Comfere T, Sprung J, Kumar MM, Draper M, Wilson DP, Williams BA, Danielson DR, Liedl L, Warner DO. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 2005 Mar;100(3):636-644. doi: 10.1213/01.ANE.0000146521.68059.A1.
- Singh A, Antognini JF. Perioperative hypotension and myocardial ischemia: diagnostic and therapeutic approaches. Ann Card Anaesth. 2011 May-Aug;14(2):127-32. doi: 10.4103/0971-9784.81569.
- Ferreira AJ, Murca TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens. 2012;2012:147825. doi: 10.1155/2012/147825. Epub 2012 Jan 26.
- Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014 Oct 6;18(5):534. doi: 10.1186/s13054-014-0534-9.
- Tallarida RJ, Stone DJ Jr, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sci. 1997;61(26):PL 417-25. doi: 10.1016/s0024-3205(97)01030-8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 3, 2019
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
November 5, 2018
First Submitted That Met QC Criteria
November 5, 2018
First Posted (Actual)
November 7, 2018
Study Record Updates
Last Update Posted (Estimate)
May 4, 2023
Last Update Submitted That Met QC Criteria
May 2, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00054661
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Angiotensin II
-
Children's Hospital Medical Center, CincinnatiCompletedEosinophilic Esophagitis | Connective Tissue DisordersUnited States
-
Norwegian University of Science and TechnologyAstraZenecaCompleted
-
Massachusetts General HospitalCompletedHypertrophic CardiomyopathyUnited States
-
University of California, San FranciscoFlight Attendant Medical Research InstituteRecruitingCardiovascular Diseases | HypertensionUnited States
-
La Jolla Pharmaceutical CompanyCompletedSepsis | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output ShockUnited States, Canada, Belgium, Australia, United Kingdom, Finland, New Zealand, France, Switzerland, Germany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Hypertension | Atherosclerosis | Heart Failure, CongestiveUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Hypertension | Atherosclerosis | Heart Failure, CongestiveUnited States
-
Nara Medical UniversityCompletedHypertension | Brain InfarctionJapan
-
Louise FaerchCompletedHypoglycemia | Type 1 DiabetesDenmark
-
NYU Langone HealthNot yet recruitingArthrofibrosis of KneeUnited States